Medical Education

July 2012 View as a webpage | Forward to a colleague | Not subscribed? Subscribe here
Advances in Transplantation
Featured Articles

HCT vs. azacitidine in high-risk MDS

In this multi-center study of patients with high-risk myelodysplastic syndromes (MDS) or secondary AML (sAML), undergoing HCT was associated with better long-term overall survival compared to receiving azacitidine (AZA) therapy. In this retrospective balanced-cohort study, 103 patients with high-risk MDS/sAML who underwent HCT were compared to 75 MDS patients receiving AZA. All patients were between 60-70 years old. A multivariate analysis revealed three factors significantly associated with greater overall survival: cytogenetics (good vs. intermediate vs. poor; hazard ratio [HR], 1.2/1.7; p=0.026), ECOG score (0 vs. 1 vs. 2; HR, 2.9/3.9; p<0.001), and treatment (HCT vs. AZA; HR, 0.3; p=0.007).

Platzbecker U, et al. Biol Blood Marrow Transplant »

Reduced-intensity HCT in adults with NHL

A multi-center study of 248 adults (median age 52 years, range 18-72) undergoing reduced-intensity HCT for non-Hodgkin lymphoma (NHL) using unrelated (n=222) and related (n=26) donors. Outcomes were reported to the CIBMTR (Center for International Blood and Marrow Transplant Research). Grade II-IV acute GVHD at 100 days was 43%, and chronic GVHD at three years was 44%. Overall and progression-free survival at three-years post HCT were 41% and 32%, respectively. In a multivariate analysis, use of antithymocyte globulin and HLA mismatch were associated with increased transplant-related mortality.

Hale GA, et al. Biol Blood Marrow Transplant »

Donor-recipient sex combination more important than donor type for AML in CR1

A retrospective, multi-center study of 605 patients with intermediate-risk acute myeloid leukemia (AML) in first complete remission (CR1) has found that males may have better transplant outcomes using a male matched unrelated donor rather than a female matched related donor. In this study, four-year overall survival (OS) was 65% for matched related HCT and 68% for matched unrelated donor HCT (p=0.50). In unrelated donor HCT with sex combinations other than female donor/male recipient, four-year OS was significantly higher compared to matched related HCT from female donors to male recipients: 72% vs. 55%; p=0.04. The authors conclude the donor-recipient sex combination may be more important than the donor type in donor selection in this patient population.

Imahashi N, et al. Bone Marrow Transplant »

Effects of marrow donation in pediatric donors

A single-center, retrospective study of 210 pediatric (<13 years) bone marrow donors, examining procedures of donor eligibility and immediate post-donation effects. The researchers also prospectively studied a cohort of childhood donors on long-term health and quality-of-life factors. Of 197 donors with analyzable data, 13 (6.6%) had existing medical conditions possibly affecting the safety of the donation. Only 24 donors had documented follow-up within 100 days of donation. The authors conclude that there is a need for “independent medical assessment of child donors, especially in children with preexisting medical conditions to avoid peri-donation events.”

van Walraven SM, et al. Bone Marrow Transplant »

Diagnosis and management of acute GVHD

The recommendations on the diagnosis and management of acute GVHD outlined in this position paper reflect the consensus opinion of HCT experts from two British professional organizations. The recommendations include GVHD grading criteria, specific recommendations based on severity of disease and organ(s) involved, primary treatment options, and second- and third-line treatment options for patients with steroid-refractory disease.

Dignan FL, et al. Br J Haematol »


Special Edition Newsletter Highlights CIBMTR Research

In celebration of the 40th anniversary of CIBMTR (Center for International Blood and Marrow Transplant Research), the NMDP has released a special edition of its Advances in Transplantation newsletter. This edition highlights the tremendous impact of CIBMTR research, and features 12 of the more than 700 publications from CIBMTR.
View newsletter (PDF) »

Test Your Knowledge

What new indication for adults with AML was added to the NMDP/ASBMT transplant consultation guidelines in 2012?

Answer Now
Other Noteworthy Articles
Tandem auto-allo-HCT is feasible in relapsed NHL

Access abstract »

HCT in systemic amyloidosis

Access abstract »

HCT in thalassemia major

Access abstract »

Unrelated donor HCT for childhood ALL

Access abstract »

Resources For You
New transplant guidelines
Phone App

Announcing new transplant care guidelines for physicians and patients, including 2012 post-transplant care guidelines, in a mobile app, print and online.

New patient-friendly post-transplant care recommendations

New clinical post-transplant guidelines and vaccination schedule

Get the updated guidelines »

Resources For Your Patients
Preventive care guidelines
Phone App

In addition to inclusion in the mobile app, patient versions of the transplant care guidelines are also available in three new, easy-to-understand brochures. These preventive care guidelines help transplant recipients prepare for follow-up care appointments, and include customized lists of tests and evaluations for 6-month, 12-month, and 2+year annual check-ups
Order now »

Visit Us Online

Access outcomes data slides, CME, clinical references, patient education and more.

Contact Us | Privacy Policy | Terms of Use | Unsubscribe | Vol. 12, No. 7  

Advances in Transplantation is an electronic newsletter published monthly by the National Marrow Donor Program (NMDP). This newsletter is sent only to those individuals who have requested to receive clinical education updates from NMDP.

If this e-mail message was forwarded to you and you'd like Advances in Transplantation delivered directly to you, please subscribe.

If you are a member of the NMDP Be The Match Registry®, unsubscribing to the Advances in Transplantation e-newsletter does not change your status on the registry. The NMDP may still contact you by e-mail, postal mail or telephone if a patient needs you or to request that you update your address.

National Marrow Donor Program, 3001 Broadway St. N.E., Minneapolis, MN 55413 | 1 (612) 627-5800 | Copyright © 2012

Copyright © 1996-2018 National Marrow Donor Program. All Rights Reserved.